In this video as part of The Motley Fool's "Ask a Fool" series, Fool health-care analyst David Williamson takes a question from a Fool reader, who asks, "Gilead Sciences (NASDAQ:GILD) seems to be on a down trend. Is there any specific reason, or should I just hold firm?"
David takes a look at Gilead's downward trend year to date but cautions that this 3% pullback since the beginning of 2014 is much better understood in the context of the stock's meteoric rise over the past 12 months. He then discusses for investors the company's hepatitis C drug Sofosbuvir, sold under the name Sovaldi, and how much of the investing thesis is based around the success of this drug. He notes that while the drug is destined to be a blockbuster with an incredible cure rate, it has its risks that investors need to be aware of. Finally, David looks at Gilead's pipeline, and the future of the company.
What's the best buy in biotech today?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.